ICON selected to validate patient-reported outcome endpoints for antibacterial trial
ICON announced it has been awarded a project by the FDA to validate three Patient Reported Outcomes instruments that will measure clinical endpoints in antibacterial drug trials. The conditions in which the endpoints will be validated are ABSSSI, CABP and HABP. February 20, 2017